Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05886491 · ClinicalTrials.gov registry record · Phase 1
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study of Leukemia, sponsored by Takeda.
- Active
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 11
- Study locations
NCT05886491 is a Phase 1 study of Leukemia that is active but no longer recruiting, run by Takeda. The registered enrollment target is 16 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower). The trial reports 11 study locations across 11 states.
The verdict
NCT05886491, a Phase 1 study of Leukemia, is active but no longer recruiting, sponsored by Takeda.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 11
- Study locations
Study Summary
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and to determine the best dose of GDX012.
Conditions Studied
Interventions
- DRUG GDX012
- DRUG Chemotherapy Agents
Study Locations (11)
Alabama
- University of Alabama at Birmingham (UAB) Hospital - Birmingham
California
- City of Hope - Duarte
Colorado
- Sarah Cannon/CBCI - Denver
Illinois
- Comprehensive Cancer Center of Northwestern University - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Missouri
- Washington University - St Louis
New York
- Thomas Jefferson University - New York
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-07-11 |
| Est. Completion | 2026-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05886491
The ClinicalTrials.gov registry entry for NCT05886491 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which GDX012 is the first listed.
NCT05886491 reports 11 study locations spanning 11 distinct geographic areas - top geographies include Alabama, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05886491 about?
NCT05886491 is a clinical study titled "A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia". GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and to determine the best dose of GDX012.
What is the current status of trial NCT05886491?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-07-11. Estimated completion is 2026-05-12.
What conditions does trial NCT05886491 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT05886491?
The interventions under investigation include: GDX012 (DRUG), Chemotherapy Agents (DRUG).
Who is sponsoring clinical trial NCT05886491?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05886491 being conducted?
This trial has 11 study locations across Alabama, California, Colorado, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.